Scientists at the University of Arkansas created a nano-drug that may eradicate triple-negative breast cancer cells.
Findings were published in Advanced Therapeutics.
"With the exception of skin cancers, breast cancer is the most common form of cancer in American women," said Hassan Beyzavi, assistant professor in the Department of Chemistry and Biochemistry. "As we know, thousands of women die from breast cancer each year. Patients with triple negative cells are especially vulnerable, because of the toxic side effects of the only approved treatment for this type of cancer. We've addressed this problem by developing a co-formulation that targets cancer cells and has no effect on healthy cells."
Learn more about triple negative breast cancer:
Triple negative breast cancer is an aggressive cancer type characterized by a lack estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. As a result, the cancer can not be treated with receptor-targeted therapy. To make matters worse, the cancer is often challenging to treat with existing chemotherapy and often needs invasive surgery.
Source: Science Daily
